Showing results (1671-1680 of 3,638) with videos related to

Sort By:
Pageof 364
Breast (Edinburgh, Scotland)|November 5, 2024
Preoperative reference values for breast cancer patients using the BREAST-QCharlotta Kuhlefelt, Jussi P Repo, Veera Rasi, et al.
Breast (Edinburgh, Scotland)|November 24, 2024
Inequality in breast cancer: Global statistics from 2022 to 2050Ling Liao
Breast (Edinburgh, Scotland)|August 13, 2024
Non-invasive prediction of axillary lymph node dissection exemption in breast cancer patients post-neoadjuvant therapy: A radiomics and deep learning analysis on longitudinal DCE-MRI dataYushuai Yu, Ruiliang Chen, Jialu Yi, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Breast (Edinburgh, Scotland)|July 6, 2024
Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitalsBo Lan, Xuenan Peng, Fei Ma
Breast (Edinburgh, Scotland)|March 28, 2024
French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategiesVincent Lavoue, Amélia Favier, Sophie Franck, et al.
Breast (Edinburgh, Scotland)|April 11, 2024
A systematic review and meta-analysis of English language online patient education materials in breast cancer: Is readability the only story?Joey Z Gu, Grayson L Baird, Antonio Escamilla Guevara, et al.
Breast (Edinburgh, Scotland)|March 23, 2024
Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral centerJohn Loggie, Penelope J Barnes, Michael D Carter, et al.
Breast (Edinburgh, Scotland)|March 30, 2024
A deep intronic recurrent CHEK2 variant c.1009-118_1009-87delinsC affects pre-mRNA splicing and contributes to hereditary breast cancer predispositionPetra Zemankova, Marta Cerna, Klara Horackova, et al.
Breast (Edinburgh, Scotland)|September 10, 2023
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, et al.
Pageof 364